CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by CD19, CD20, or HER2 CAR-T cells. These luciferase expressing cell lines were derived from ...

As interest in immunotherapy grows, so does the need for better tools to engineer CAR T cells. Could advances in CRISPR technology be the solution? In the last decade, a new immunotherapy tool has ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

Researchers have discovered that some CAR-T cells engineered to fight cancer and other conditions carry the memory of past encounters with bacteria, viruses and other antigens within them ...

Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug (IND) application to begin ...

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s ...

The study, published today in the journal Nature Immunology, focused on chimeric antigen receptor (CAR)-T cells, an effective therapy against cancer, especially leukemia and lymphoma.

Site selection for CAR T-cell clinical trials is a complex process that requires the right expertise, capability, and facility. Infrastructure is another major factor to consider as patients will ...

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-effects ...

and automated instrument workflows improve CAR T cell manufacturing. Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological ...